INTRODUCTION: Primary hyperparathyroidism (pHPT) is caused by a single monoclonal adenoma in more than 80% of patients. Biomolecular mechanisms causing pHPT are still not completely known, even if a great amount of studies have been developed recently, mainly regarding angiogenesis and growth factors. Among the latter, insulin-like growth factor 1 (IGF-1), basic fibroblastic growth factor (bFGF), vascular endothelial growth factor (VEGF), and transforming growth factor beta 1 (TGF-beta1) and their effects have been extensively evaluated in different kinds of endocrine disease. METHODS: Parathyroid cell cultures were prepared from six human adenomatous parathyroid glands that were surgically removed. After 7 days of culture, the cells were refed with DMEM supplemented with 2% FCS alone (control group), or containing hrTGFbeta1, or hrIGF-I, or hrbFGF, or hrVEGF. Then, after 48-hour incubation, cell count was performed by a particle count and size analyzer, and prevalence of cell cycle was analyzed by using a flow cytometer. RESULTS: Cell count (x10000) in the control group was 3.73 +/- 0.32. Low-dose TGF-beta1 stimulation resulted in 5.25 +/- 0.38 cells, and high-dose TGF-beta1 stimulation resulted in 2.35 +/- 0.37 cells. IGF-1 stimulation resulted in 5.4 +/- 0.65 cells, bFGF stimulation in 5.68 +/- 0.86 cells, and VEGF stimulation resulted in 6.03 +/- 1.03 cells. Statistical analysis revealed significant differences in the control group compared with the growth factor-stimulated groups. Cytometry showed different results in the percentage of cells in S-phase, in particular 22.65 +/- 4.98% of IGF-1-stimulated cells were found in S-phase compared with 7.55 +/- 3.2% of control group cells (p < 0.0001). CONCLUSIONS: Growth factors seem to play an important role in parathyroid adenoma cell proliferation; IGF-1, bFGF, VEGF, and low-dose TGF-beta1 promote cell proliferation, whereas high-dose TGF-beta1 inhibits these phenomena.
INTRODUCTION:Primary hyperparathyroidism (pHPT) is caused by a single monoclonal adenoma in more than 80% of patients. Biomolecular mechanisms causing pHPT are still not completely known, even if a great amount of studies have been developed recently, mainly regarding angiogenesis and growth factors. Among the latter, insulin-like growth factor 1 (IGF-1), basic fibroblastic growth factor (bFGF), vascular endothelial growth factor (VEGF), and transforming growth factor beta 1 (TGF-beta1) and their effects have been extensively evaluated in different kinds of endocrine disease. METHODS: Parathyroid cell cultures were prepared from six humanadenomatous parathyroid glands that were surgically removed. After 7 days of culture, the cells were refed with DMEM supplemented with 2% FCS alone (control group), or containing hrTGFbeta1, or hrIGF-I, or hrbFGF, or hrVEGF. Then, after 48-hour incubation, cell count was performed by a particle count and size analyzer, and prevalence of cell cycle was analyzed by using a flow cytometer. RESULTS: Cell count (x10000) in the control group was 3.73 +/- 0.32. Low-dose TGF-beta1 stimulation resulted in 5.25 +/- 0.38 cells, and high-dose TGF-beta1 stimulation resulted in 2.35 +/- 0.37 cells. IGF-1 stimulation resulted in 5.4 +/- 0.65 cells, bFGF stimulation in 5.68 +/- 0.86 cells, and VEGF stimulation resulted in 6.03 +/- 1.03 cells. Statistical analysis revealed significant differences in the control group compared with the growth factor-stimulated groups. Cytometry showed different results in the percentage of cells in S-phase, in particular 22.65 +/- 4.98% of IGF-1-stimulated cells were found in S-phase compared with 7.55 +/- 3.2% of control group cells (p < 0.0001). CONCLUSIONS: Growth factors seem to play an important role in parathyroid adenoma cell proliferation; IGF-1, bFGF, VEGF, and low-dose TGF-beta1 promote cell proliferation, whereas high-dose TGF-beta1 inhibits these phenomena.
Authors: Andreas C Lazaris; Sofia Tseleni-Balafouta; Thomas Papathomas; Theodore Brousalis; Georgia Thomopoulou; George Agrogiannis; Efstratios S Patsouris Journal: Eur J Endocrinol Date: 2006-06 Impact factor: 6.664
Authors: Jaromír Astl; David Veselý; Petr Matucha; Jindrich Martínek; Tomás Kucera; Petr Lastuvka; Jan Betka; Ivan Sterzl Journal: Neuro Endocrinol Lett Date: 2004-10 Impact factor: 0.765
Authors: Natalie E Cusano; Mishaela R Rubin; Chiyuan Zhang; Laura Anderson; Elizabeth Levy; Aline G Costa; Dinaz Irani; John P Bilezikian Journal: J Clin Endocrinol Metab Date: 2014-08-19 Impact factor: 5.958
Authors: Özer Makay; Beyza Özçınar; Turgay Şimşek; Cumhur Arıcı; Bülent Güngör; Serdar Özbaş; Tamer Akça; Ali Uğur Emre; Güldeniz Karadeniz Çakmak; Müfide Akçay; Bülent Ünal; Mustafa Girgin; Sadullah Girgin; Semih Görgülü; Atakan Sezer; Adem Karataş; İbrahim Ali Özemir; Nihat Aksakal; Serap Erel; M Ümit Uğurlu; Ali İlker Filiz; Can Atalay; Ali Uzunköy; Uğur Deveci; Çetin Kotan; Gökhan İçöz; Yavuz Kurt; Abut Kebudi; N Zafer Cantürk; Yeşim Erbil; Rumen Pandev; Bahadır M Güllüoğlu Journal: Balkan Med J Date: 2017-01-05 Impact factor: 2.021